Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Strong-Buy at Zacks Research

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports.

A number of other equities analysts have also weighed in on the stock. UBS Group upped their price target on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Royal Bank Of Canada lifted their target price on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 29th. Canaccord Genuity Group increased their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Guggenheim raised their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Finally, Wells Fargo & Company boosted their price objective on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “equal weight” rating in a research report on Wednesday, December 10th. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $791.05.

Regeneron Pharmaceuticals Stock Down 0.6%

NASDAQ REGN opened at $796.55 on Thursday. The stock’s 50-day moving average price is $738.12 and its 200-day moving average price is $628.06. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $821.11. The company has a market capitalization of $83.72 billion, a P/E ratio of 19.07, a price-to-earnings-growth ratio of 2.17 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm’s revenue was up .9% on a year-over-year basis. During the same period in the previous year, the company posted $12.46 EPS. On average, equities research analysts predict that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 8,431 shares of company stock valued at $5,733,521 in the last 90 days. Insiders own 7.02% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds have recently modified their holdings of REGN. Salomon & Ludwin LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Regeneron Pharmaceuticals during the second quarter valued at $31,000. Board of the Pension Protection Fund bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $31,000. Caitlin John LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $34,000. Finally, Traub Capital Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $38,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Multiple analyst upgrades and higher targets — Bank of America and other firms raised ratings/targets this week, shifting consensus toward Buy and boosting investor confidence. Bank of America upgrade
• Positive Sentiment: Zacks moved REGN to a Zacks Rank #1 (Strong Buy), highlighting expectations for continued earnings outperformance. Zacks upgrade
• Positive Sentiment: Truist and other brokers raised price targets (Truist to $820), and aggregated analyst coverage (21‑analyst notes) points to a more favorable fundamental outlook — a catalyst for momentum buyers. 21‑analyst roundup
• Neutral Sentiment: Unusual options activity has picked up around REGN, signaling elevated trader interest and potential for amplified short‑term moves; direction is ambiguous. Unusual options activity
• Neutral Sentiment: Comparative analyst pieces (REGN vs peers) provide valuation context but are not immediate catalysts. REGN vs ILMN analysis
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at roughly $800 — a small dollar amount relative to market cap but sometimes triggers investor concern and short‑term profit‑taking. Insider sale SEC filing

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.